Last reviewed 2026-05-26 · How we verify

Treatment of Encorafenib & Binimetinib & Ribociclib (treatment-of-encorafenib-binimetinib-ribociclib)

Pfizer Inc. · preclinical active Under review Quality 0/100

Treatment of Encorafenib & Binimetinib & Ribociclib (generic name: treatment-of-encorafenib-binimetinib-ribociclib) is a Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime drug developed by Pfizer Inc.. It is currently in preclinical development.

Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime

Ribociclib is a small molecule inhibitor of Cyclin-dependent kinase 4. It is used in the treatment of cancer and solid tumors, as indicated by ClinicalTrials.gov.

Likelihood of approval

8% vs 5% industry baseline

If approved by FDA: likely 2036–2040

Steps remaining: Phase 1 → Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Low

Why this estimate

Baseline preclinical → approval rate +5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2036–2040	—
EMA	EU	2037–2041	+0.7 yr
MHRA	GB	2037–2041	+0.7 yr
Health Canada	CA	2037–2042	+0.9 yr
TGA	AU	2037–2042	+1.2 yr
PMDA	JP	2037–2042	+1.5 yr
NMPA	CN	2038–2043	+2.3 yr
MFDS	KR	2037–2042	+1.4 yr
CDSCO	IN	2037–2043	+1.8 yr
ANVISA	BR	2038–2043	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	treatment-of-encorafenib-binimetinib-ribociclib
Sponsor	Pfizer Inc.
Drug class	Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime
Therapeutic area	Oncology
Phase	preclinical

Approved indications

No approved indications tracked.

Pipeline indications

Solid Tumors — preclinical

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Treatment of Encorafenib & Binimetinib & Ribociclib CI brief — competitive landscape report
Treatment of Encorafenib & Binimetinib & Ribociclib updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about Treatment of Encorafenib & Binimetinib & Ribociclib

What is Treatment of Encorafenib & Binimetinib & Ribociclib?

Treatment of Encorafenib & Binimetinib & Ribociclib (treatment-of-encorafenib-binimetinib-ribociclib) is a Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime drug developed by Pfizer Inc..

How does Treatment of Encorafenib & Binimetinib & Ribociclib work?

Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime

Who makes Treatment of Encorafenib & Binimetinib & Ribociclib?

Treatment of Encorafenib & Binimetinib & Ribociclib is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Treatment of Encorafenib & Binimetinib & Ribociclib?

treatment-of-encorafenib-binimetinib-ribociclib is the generic (nonproprietary) name of Treatment of Encorafenib & Binimetinib & Ribociclib.

What drug class is Treatment of Encorafenib & Binimetinib & Ribociclib in?

Treatment of Encorafenib & Binimetinib & Ribociclib belongs to the Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime class. See all Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime drugs at /class/encorafenib-capsule-and-ribociclib-capsules-or-tablets-will-be-co-administered-orally-qd-with-binime.

What development phase is Treatment of Encorafenib & Binimetinib & Ribociclib in?

Treatment of Encorafenib & Binimetinib & Ribociclib is in preclinical.

Drug class: All Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime drugs
Manufacturer: Pfizer Inc. — full pipeline
Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing